Technical & Scientific
Due Diligence
Biotech Investor Risk Mitigation
Reimagining Drug Development for Good
The world of drug development must evolve to keep pace with the growing need for speed, innovation, and efficiency. Imagine Biotech leads this transformation to de-risk private biotech investors by harnessing predictive simulations, advanced data modeling, and AI solutions specifically designed for drug discovery and development.
Latest News & Technology We Use
About
Imagine Biotech
Imagine Biotech resources can call upon a wide variety of industry experts and technologies to de-risk your biotech portfolio using sophisticated pathways that have matured due to improved data resources.
​
Our array of services ranges from advanced molecular modeling techniques such as density functional theory (DFT) to a first-of-its-kind integration package combining ADMET and PK predictions with academic-level risk assessment.
​
We use FDA approved AnimalGAN and Digital Animal Replacement Technology (DART) to simulate animal responses using historical data and human biology, reducing the need for new animal testing. These tools provide ethical, scalable, and data-driven insights that support more accurate early-stage decision-making.
​
Our team identifies the right tests and technologies to support further investment success or flags potential red flags that arise only under the scrutiny of seasoned biotechnology professionals.
​
Depending on the sector, be it antibiotics, oncology, metabolic disease, or diagnostics specific assets and simulations are included in the tailored reports we generate for investors. In many cases, our reviews cost less than traditional legal due diligence.
ADMET prediction with PK modeling
AnimalGAN - Simulate synthetic animal data
Mass spectrometry assets
Bioinformatics & Metabolite databases
3D protein modelling and molecular docking
Toxicology | Drug delivery & infusion
Chromatography Techniques
The Importance of Knowing Your Molecule Before you Invest Time and Capital
Approximately 30% of drug failures in clinical trials are due to unmanageable toxicity.
About 18% of drug failures are specifically due to drug-induced liver injury (DILI).
Drug toxicity can result from both off-target and on-target inhibition of molecular targets.
Toxicity issues are oftennot detected until clinicaltrials, despite rigorouspreclinical testing in animalmodels.
Many potential drugs fail due to misclassification by animal models, which may not accurately predict human toxicity.
The high failure rate due to toxicity underscores the importance of improved methods for predicting and assessing drug safety early on.
GlycoMira Therapeutics, Inc.
" GlycoMira is developing a first-in-class bi-modal immune modulating anti-tumor therapeutic that has the potential the establish a new paradigm for the treatment of solid tumors.
​
The data from Imagine Biotech using sophisticated technologies on our lead drug candidate will greatly accelerate our clinical development program and reduce risk as we move forward with first in human clinical investigations.
​
Imagine Biotech's risk reduction tools should be considered essential for any drug development company.
- Sincerely,"
Dr. William Tew (CEO)
"Sometimes it is the people no one can imagine anything of, who do the things no one can imagine."
- Alan Turing
The Investor Problem
Amid economic instability and previous biotech setbacks, investors, especially Limited Partners, face declining confidence. Bottom line is that it becomes harder to close future funding rounds because of this higher historic risk profile associated to life science projects.
​
Traditionally, biotech investments centred on conventional business due diligence often overlook or don’t place heavy emphasis on meticulous technical analysis due to high associated cost.
Undesirable pharmacokinetics and toxicity are major reasons for drug development failures, with safety and efficacy of major concern for project success, recognizing drug ADMET properties early reduces clinical phase failure rates.
What The Numbers Show
$6M
Average spend on pre-clinical toxicology studies
12
Drug discovery can take 12 years and cost $2.6 billion.
90%
Clinical drugs fail, costing investors & partners millions
45%
Fail because of limited pre-clinical efficacy
30%
Fail because of unmanageable toxicity
Relations
.png)
.png)